| ¿µ¹® | peptide | ÇÑ±Û | ÆéƼµå |
|---|---|---|---|
| ¼³¸í | µÎ °³ÀÌ»óÀÇ ¾Æ¹Ì³ë»ê ºÐÀÚ »çÀÌ¿¡¼, ÇÑÂÊÀÇ ¾Æ¹Ì³ë±â¿Í ´Ù¸¥ ÂÊÀÇ Ä«¸£º¹½Ç±â°¡ ¹° ºÐÀÚ¸¦ ÀÒÀ¸¸é¼ ÃàÇÕÇÏ¿© ÀÌ·ç´Â ¾Æ¹Ìµå °áÇվƹ̳ë»êÀÇ ¼ö°¡ 2, 3, ¡¦ ÀÎ °æ¿ì, °¢°¢ µðÆéƼµå, Æ®¸®ÆéƼµå, ¡¦µîÀ¸·Î ºÎ¸£¸ç, ¿©·¯ °³ÀÇ ¾Æ¹Ì³ë»êÀ¸·Î ±¸¼ºµÇ´Â °ÍÀ» ¿Ã¸®°íÆéƼµå, À̺¸´Ù Å« °ÍÀ» Æú¸®ÆéƼµå¶ó°í ÇÑ´Ù. Á÷¼â»óÀÇ °ÍÀÌ ¸¹Áö¸¸, ȯ»ó ±¸Á¶¸¦ °®´Â ÆéƼµåµµ ÀÖ´Ù. ÀúºÐÀÚÀÇ ÆéƼµå´Â ¹°, »ê, ¾ËÄ®¸® µûÀ§¿¡ Àß ³ì°í ¾ËÄڿÿ¡´Â ³ìÁö ¾ÊÀ¸³ª, °íºÐÀÚÀÇ ÆéƼµå´Â ¹°¿¡ Àß ³ìÁö ¾Ê°í ´Ü¹éÁú°ú ¼ºÁúÀÌ ºñ½ÁÇÏ´Ù. ³úÇϼöüȣ¸£¸ó, ºê¶óµðŰ´Ñ µî°ú °°ÀÌ »ý¸®Àû±â´ÉÀÌ ÇöÀúÇÑ °ÍÀº »ý¸®È°¼ºÆéƼµå(bioactive peptide)¶ó°í ÇÑ´Ù. |
||
| ¿µ¹® | organic brain syndrome | ÇÑ±Û | ±âÁúÀû ³úÁõÈıº |
|---|---|---|---|
| ¼³¸í | ³úÀÇ ±âÁúÀûÀÎ(organic-:ÀÌ ¸»Àº ±â´ÉÀûÀÎ(functional)¿¡ ¹ÝÇÏ´Â ¸»·Î½á) ¸ðµç °Ë»ç¸¦ ½ÃÇàÇÏ¸é ¾î¶² ÀÌ»óÀ» ¹ß°ßÇÒ ¼ö ÀÖ´Ù´Â ¶æÀÌ´Ù. ¹Ù²Ù¾î ¸»Çϸé, ±â´ÉÀûÀÎ ÀÌ»ó¿¡ ÀÇÇÑ ³úÁõÈıºÀº ¾î¶°ÇÑ °Ë»ç·Îµµ ÀÌ»óÀ» ¹ß°ßÇÒ ¼ö ¾øÀ¸³ª ºÐ¸íÈ÷ ȯÀÚ¿¡°Ô ÀÌ»óÁõ»óÀÌ ³ªÅ¸³µÀ» ¶§ À̸¦ ¹¾î¼ ¸»ÇÑ´Ù. ÀÌ»ó¿¡ ÀÇÇØ ½Å°æÇÐÀûÀÎ ÀÌ»óÀ» ³ªÅ¸³»´Â ÀÏ·ÃÀÇ º´ÀûÇö»óÀ» ¸ðµÎ ÅëÆ²¾î ¸»ÇÑ´Ù. ÀÌ º´Àº ÈçÈ÷ º¸¾Æ ¸¶Ä¡ Á¤½Åº´È¯ÀÚó·³ ¸»À» Ⱦ¼³¼ö¼³Çϰí, ¾Ë¾ÆµéÀ» ¼ö ¾ø´Â ¸»À» Çϸç, ¶§·Î´Â ´Ù¸¥ »ç¶÷¿¡°Ô °ø°ÝÀûÀÎ ¼ºÇâÀ» ³ªÅ¸³»±âµµ ÇÑ´Ù. ±×¸®°í ´Ù¸¥ »ç¶÷°ú µµÀúÈ÷ ±³·ù¸¦ ÇÒ ¼ö ¾ø´Â Á¤¼¸¦ ³ªÅ¸³»±âµµ ÇÑ´Ù. ±×·¯³ª, ÀÌ º´ÀÌ ´Ù¸¥ Á¤½Åº´°ú ±¸º°µÇ´Â Ư¡ÀûÀÎ Áõ»óÀº ¸ÕÀú, ÀǽÄÀÇ È¥Å¹ÀÌ µ¿¹ÝµÇ´Â °æ¿ì°¡ ¸¹°í, ¶ÇÇÑ ±× Áõ»óÀÇ Á¤µµ°¡ º¯ÇÑ´Ù´Â °ÍÀÌ´Ù. Áï, ¾ÆÄ§¿¡´Â Á¤»óÀûÀÎ ÇൿÀ» ÇÏ´Ù°¡ ¿ÀÈİ¡ µÇ¸é, ÀǽÄÀÌ Èå·ÁÁö¸é¼ ¸»À» Ⱦ¼³¼ö¼³ÇÑ´Ù¸é, ÀÌ´Â ±âÁú¼º³úÁõÈıºÀÏ °¡´É¼ºÀÌ ³ô´Ù. |
||
| ¿µ¹® | brain death | ÇÑ±Û | ³ú»ç |
|---|---|---|---|
| ¼³¸í | ³ú±â´ÉÀÌ ¿ÏÀüÈ÷ Á¤ÁöµÇ¾î ȸº¹ ºÒ´ÉÇÑ »óÅÂ. ³úÀÇ ±â´É¿¡´Â ´ë³ú¹Ý±¸ÀÇ ±â´É À̿ܿ¡ ³ú°£ÀÇ ±â´Éµµ Æ÷ÇԵȴÙ. ³ú»ç´Â Àΰ£ÀÇ Á×À½°ú °°Àº ¶æÀÌ ¾Æ´Ï°í, º¸ÅëÀº ³ú»ç ´ÙÀ½¿¡ Á×À½ÀÌ ¿Â´Ù. ½ÉÀåÀÌ½Ä ¼ö¼ú¿¡´Â °¡´ÉÇÑ ÇÑ ½Å¼±ÇÑ ½ÉÀåÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ ½ÉÀå Á¦°øÀÚÀÇ Á×À½À» ³ú»ç·Î ±ÔÁ¤ÇÏ·Á´Â ¿òÁ÷ÀÓÀÌ ÀÖ¾ú´Ù. 1968³â 8¿ù ¼¼°èÀÇ»çȸ ÃÑȸ¿¡¼ äÅÃµÈ Àå±âÀ̽Ŀ¡ °üÇÑ ¼±¾ð(½Ãµå´Ï ¼±¾ð)¿¡¼´Â ¨ç ½ÉÀå Á¦°øÀÚÀÇ Á×À½ÀÇ ÆÇÁ¤Àº ³úÆÄÃøÁ¤»óÀÇ ³úÆÄÀÇ Á¤Áö(³ú»ç)·Î °áÁ¤ÇØ¾ß ÇÑ´Ù. ¨è Á¦°øÀÚÀÇ Á×À½À» È®ÀÎÇϴµ¥ µÎ¸íÀÌ»óÀÇ Àǻ簡 ÀÔÈ¸ÇØ¾ß Çϸç, ³ú»çÀÇ °áÁ¤¿¡ Âü¿©ÇÑ ÀÇ»ç´Â À̽ļö¼ú¿¡ °ü¿©Çؼ´Â ¾È µÈ´Ù°í Çß´Ù. ±×·¯³ª ³úÆÄÃøÁ¤¸¸À¸·Î´Â ³úÁÙ±âÀÇ ±â´ÉÁ¤Áö¸¦ ÆÇÁ¤ÇÒ ¼ö ¾ø°í, ³ú»çÀÇ ÆÇÁ¤µµ Áúº´ÀÇ Á¾·ù³ª Áøµµ¿¡ µû¶ó ±âÁØÀÌ ´Þ¶óÁö¹Ç·Î ÆÇÁ¤±âÁØÀÇ °ËÅä°¡ ÇÊ¿äÇÏ´Ù. ³úÁ¾¾ç-³ú¿Ü»ó-Ç÷ÇàÀå¾Ö µî ³úÁúȯÀÇ Áõ·Ê¿¡¼ º¸¸é ¨ç ±íÀº È¥¼ö, ¨è ¾çÂÊ µ¿°øÀÇ È®´ë ¹× µ¿°øÀÇ ºû¹Ý»ç¿Í °¢¸·¹Ý»çÀÇ ¼Ò½Ç, ¨é È£ÈíÀÇ Á¤Áö, ¨ê ³úÆÄÀÇ ÆòźÈ, ¨ë Ç÷¾ÐÀÇ ±Þ°ÝÇÑ ÀúÇÏ¿Í ±×¿¡ µû¸¥ ÀúÇ÷¾Ð µî ´Ù¼¸ °¡Áö Á¶°ÇÀÌ 6½Ã°£ ÈÄ¿¡µµ µ¿ÀÏÇÑ »óÅ¿¡ ÀÖ´Â °Í µî ¿©¼¸°¡Áö Á¶°ÇÀÌ ÆÇÁ¤ ±âÁØÀÌ µÇ¾ú¾ú´Ù. ÇöÀç´Â °¡Àå °·ÂÇÑ µ¿ÅëÀڱؿ¡ ´ëÇØ¼µµ ÀüÇô ¾Æ¹«·± °¨¼ö¼º°ú ¹ÝÀÀ¼ºÀ» ³ªÅ¸³»Áö ¾Ê´Â 24½Ã°£¿¡ °ÉÄ£ È¥¼ö·Î¼, Àڹ߿ ¶Ç´Â ÀÚ¹ßÈ£ÈíÀÌ ¾ø°í À¯¹ß¹Ý»ç°¡ ¼Ò½ÇµÇ°í ³úÀÇ Àü±âȰµ¿ÀÌ ¾ø¾îÁö´Â ȸº¹ºÒ°¡´ÉÇÑ ÀǽļҽÇÀ̶ó°í Á¤ÀÇÇϰí ÀÖ´Ù. |
||
| ¿µ¹® | brain tumor | ÇÑ±Û | ³úÁ¾¾ç |
|---|---|---|---|
| ¼³¸í | ³úÁ¾¾çÀ̶õ ³ú¿Í ³úÁ¶Á÷¿¡¼ »ý±ä Á¾¾çÀ» ÁöĪÇÏ´Â ¸»ÀÌ´Ù. ±×·¯³ª ´ë°³ ³ÐÀº Àǹ̷Π»ç¿ëÇÒ °æ¿ì¿¡´Â ¸Ó¸®»À¼ÓÀÇ °ø°£ÀÎ µÎ°³°¼Ó¿¡ »ý±â´Â ¸ðµç Á¾¾çÀ» À̸£´Â ¸»·Î »ç¿ëµÈ´Ù. ³úÁ¾¾çÀº ÇÑÁ¤µÈ °ø°£ÀÎ µÎ°³°¿¡¼ ¹ß»ýÇϹǷΠÁ¾¾çÀÌ ±×´ÙÁö Å©Áö ¾Ê¾Æµµ Á¤»óÀûÀÎ Á¶Á÷À» ¾Ð¹ÚÇÏ°Ô µÇ°í, µÎ°³°³»ÀÇ ¾Ð·ÂÀ» ³ôÀδÙ. ÀÌ·± Ư¡¿¡ ÀÇÇØ¼ ³úÁ¾¾çÀÇ Áõ»óÀº ´Ù¸¥ Á¾¾ç°ú ´Þ¸®, Á¾¾ç ±× ÀÚüÀÇ Áõ»óº¸´Ùµµ µÎ°³³»¾Ð»ó½Â°ú Á¤»óÁ¶Á÷ÀÇ ¾Ð¹Ú¿¡ ÀÇÇÑ Áõ»óÀÌ ¸¹´Ù. µÎ°³³»¾Ð(³ú¾Ð)ÀÇ »ó½Â¿¡ ÀÇÇÑ Áõ»óÀ¸·Î´Â µÎÅë, ±¸ÅäµîÀÌ ÀÖÀ¸¸ç, Áö¼ÓÀûÀÎ ³ú¾Ð»ó½Â¿¡ ÀÇÇØ¼ À¯µÎºÎÁ¾(papilledema)ÀÌ °üÂûµÇ±âµµ ÇÑ´Ù. ±×¸®°í Á¤»óÀûÀÎ ³úÁ¶Á÷ÀÇ ¾Ð¹Ú°ú Á¾¾çÀÌ »ý±ä ºÎÀ§ÀÇ ±â´ÉÀÇ °áÇÕ¿¡ ³úÀÇ ±× ºÎºÐ¿¡ ÇØ´çÇÏ´Â ±â´ÉÀÇ »ó½ÇÀ» º¸°ÔµÈ´Ù. |
||
| BD | barbital-dependent; barbiturate dependence; base deficit; base of prism down; basophilic degeneratio... |
|---|---|
| C-Peptide | Connecting Peptide |
| ERP | early receptor potential; effective refractory period; elodoisin-related peptide; endoscopic retrogr... |
| VIP | vasoactive intestinal peptide; vasoinhibitory peptide; venous impedance plethysmography; ventricular... |
| GUT | Genito-Urinary Tract |
| gut GLI | Gut glucagon-like immunoreactivity |
|---|---|
| GALT | Gut associated lymphoid tissue |
| GKLF | Gut-enriched Kruppel-like factor |
| WGTT | Whole gut transit time |
| GALT | gut associated lymphoreticular tissues |
corticotropin-releasing factor (ºÎ½Å ÇÇÁú È£¸£¸ó À¯¸® ¿ä¼Ò, ºÎ½Å ÇÇÁú È£¸£¸ó À¯¸® ÀÎÀÚ
| brain natriuretic peptide | <hormone, protein> Brain peptide that induces diuresis, related to atrial natriuretic peptide. (18 Nov 1997) |
|---|---|
| blind gut | <anatomy> A blind pouch-like commencement of the colon in the right lower quadrant of the abdomen at the end of the small intestine. The appendix is a diverticulum that extends off the caecum. (13 Nov 1997) |
| gut | 1. A narrow passage of water; as, the Gut of Canso. 2. An intenstine; a bowel; the whole alimentary canal; the enteron; (pl) bowels; entrails. 3. One of the prepared entrails of an animal, especially. Of a sheep, used for various purposes. See Catgut. 4. The sac of silk taken from a silkworm (when ready to spin its cocoon), for the purpose of drawing it out into a thread. This, when dry, is exceedingly strong, and is used as the snood of a fish line. Blind gut. See Caecum, . Origin: OE. Gut, got, AS. Gut, prob. Orig, a channel, and akin to geotan to pour. See FOUND to cast. Source: Websters Dictionary (01 Mar 1998) |
| gut-associated lymphoid tissue | <physiology> Peripheral lymphoid organ consisting of lymphoid tissue associated with the gut (Peyer's patches, tonsils, mesenteric lymph nodes and the appendix). It is especially rich in B-cells and is responsible for localised immunity to pathogens such as bacteria, viruses, and parasites. (20 Sep 2002) |
| postanal gut | An extension of the hindgut caudal to the point at which the anal opening is formed. Synonym: postcloacal gut, tailgut. (05 Mar 2000) |
| postcloacal gut | An extension of the hindgut caudal to the point at which the anal opening is formed. Synonym: postcloacal gut, tailgut. (05 Mar 2000) |
| preoral gut | The part of the embryonic foregut extending cephalad to the level of the oral plate and caudal to the pituitary diverticulum (Rathke's pouch). Synonym: preoral gut. (05 Mar 2000) |
| primitive gut | A flat sheet of intraembryonic endoderm that will change into a tubular gut due to the folding of embryonic body-head, tail and lateral body folds. Synonym: archenteron, celenteron, endodermal canal, subgerminal cavity. (05 Mar 2000) |
| endocrine cells of gut | Cells found throughout the lining of the gastrointestinal tract that contain regulatory peptide hormones and/or biogenic amines. The substances are located in secretory granules and act in an endocrine or paracrine manner. Some of these substances are also found in neurons in the gut. There are at least 15 different types of endocrine cells of the gut. Some take up amine precursors and have been called apud cells. However, most endocrine cells of the gut apparently have endodermal rather than neuroectodermal origin, so the relationship with apud cells is not clear. (12 Dec 1998) |
| alpha-aminoacyl-peptide hydrolases | <enzyme> Registry number: EC 3.4.11. (12 Dec 1998) |
| anionic neutrophil activating peptide | <cytokine> A cytokine that activates neutrophils and attracts neutrophils and T-lymphocytes. It is released by several cell types including monocytes, macrophages, T-lymphocytes, fibroblasts, endothelial cells, and keratinocytes by an inflammatory stimulus. Il-8 is a member of the beta-thromboglobulin superfamily and structurally related to platelet factor 4. Acronym: IL-8 (12 Dec 1998) |
| antibiotics, peptide | Antibiotics whose structure contains one or more peptides, usually cyclic. They are generally effective against gram-positive bacteria and act by inhibiting peptidoglycan synthesis in bacterial cell walls. (12 Dec 1998) |
| atrial natriuretic peptide | <hormone> This cardiac hormone (28 amino acid residues) regulates salt and water balance in body fluids and blood pressure, it has potential as a medication to treat heart and kidney failure and the buildup of excess fluid in tissue. (09 Oct 1997) |
| bradykinin-potentiating peptide | <chemical> 2-l-tryptophan-3-de-l-leucine-4-de-l-proline-8-l-glutamine bradykinin potentiator b. A synthetic nonapeptide with the sequence pyr-trp-pro-arg-pro-gln-ile-pro-pro, which is identical to that of the peptide from the venom of the snake, bothrops jararaca. It acts as an inhibitor of kininase II and angiotensin I and has been proposed as an antihypertensive agent. Pharmacological action: angiotensin-converting enzyme inhibitors, antihypertensive agents. Chemical name: Bradykinin potentiator B, 2-L-tryptophan-3-de-L-leucine-4-de-L-proline-8-L-glutamine- (12 Dec 1998) |
| calcitonin gene-related peptide | <protein> A second product transcribed from the calcitonin gene. Calcitonin gene related peptide is found in a number of tissues including nervous tissue. It is a vasodilator that may participate in the cutaneous triple response. It is a neuropeptide of 37 amino acids with structural homology to salmon calcitonin. Co-localises with substance P in neurons. It occurs as a result of alternative processing of mRNA from the calcitonin gene. The neuropeptide is widely distributed in neural tissue of the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator. Intracerebral administration leads to a rise in noradrenergic sympathetic outflow, a rise in blood pressure and a fall in gastric secretion. Acronym: CGRP (05 May 2002) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|